References
- Sharma DC, Arya A, Kishor P, Woike P, Bindal J. Overview on thalassemias: a review article. Medico Research Chronicles. 2017; 4: 325-337. https://bp.bookpi.org/index.php/bpi/catalog/book/272.
- Angastiniotis M, Lobitz S. Thalassemias: an overview. International Journal of Neonatal Screening 2019; 5: 16. https://doi.org/10.3390/ijns5010016.
- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008; 86; 480–487. https://pubmed.ncbi.nlm.nih.gov/18568278/#:~:text=doi%3A%2010.2471/blt.06.036673.
- Galanello R, Origa R. Beta-thalassemia. Orphanet journal of rare diseases. 2010; 5: 1-15. https://doi.org/10.1186/1750-1172-5-11.
- Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. Wintrobe's Clinical Hematology.2004; 42:1319-1365.
- Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M.Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005; 127:1523-1530. https://doi.org/10.1378/chest.127.5.1523.
- Altıparmak H, Kaba Ş, Yuvalı M. Evaluation of HCV Infection Laboratory Test Results Using Machine Learning Methods. In International Conference on Theory and Application of Soft Computing, Computing with Words and Perceptions (pp. 261-269). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-030-92127-9_37.
- Cappellini, M, Cohen A, Eleftheriou A, Piga A, Porter J, Tahe A. Guidelines for the clinical management of thalassaemia [Internet] 2014 p. 261-269. http://www.ncbi.nlm.nih.gov/books/NBK173968/.
- Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 106:1460–1465. https://doi.org/10.1182/blood-2004-10-3982.
- Prakash A, Aggarwal R. Thalassemia major in adults: short stature, hyperpigmentation, inadequate chelation, and transfusion-transmitted infections are key features. North American journal of medical sciences. 2012; 4: 141–144 https://doi.org/10.4103%2F1947-2714.93886.
- Porcu M, Landis N, Salis S, Corda M, Orru P, Serra E, Usai B, Matta G, Galanello R. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure. European journal of heart failure.2007; 9:320-322. https://doi.org/10.1016/j.ejheart.2006.08.006
- Nigam N, Kushwaha R, Yadav G, Singh PK, Gupta N, Singh B, et al. A demographic prevalence of β Thalassemia carrier and other hemoglobinopathies in adolescent of Tharu population. Journal of Family Medicine and Primary Care.2020; 9:4305-10. https://doi.org/10.4103%2Fjfmpc.jfmpc_879_20.
- Saleh HA, Alkhateep YM, Mohammed AN. Role of splenectomy in thalassemic patients. Menoufia Medical Journal. 2018; 31: 118–125.https://www.mmj.eg.net/article.asp?issn=1110-2098;year=2018;volume=31;issue=1;spage=118;epage=125;aulast=Saleh.
- Langhi Jr, D, Ubiali EMA, Marques Jr, JFC, Verissimo MDA, Loggetto SR, Silvinato A, & BernardoWM. Guidelines on Beta-thalassemia major-regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira-2016. Revista brasileira de hematologia e hemoterapia. 2016; 38: 341-345. https://doi.org/10.1016/j.bjhh.2016.09.003.
- Al-Moshary M, Imtiaz N, Al-Mussaed E, Khan A, Ahmad S, Albqami S, Albqami SN. Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion-dependent thalassemia patients. Cureus. 2020; 12. DOI 10.7759/cureus.7574.
- Ondei, LDS, Estevao IDF, Rocha MIP, Percário S, Souza DRS, Pinhel MADS, Bonini-Domingos CR. Oxidative stress and antioxidant status in beta-thalassemia heterozygotes. Revista brasileira de hematologia e hemoterapia.2013; 35: 409-413. https://doi.org/10.5581/1516-8484.20130122.
- Porter JB, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. International journal of hematology.2011; 94:453-460. https://doi.org/10.1007/s12185-011-0927-3.
- De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia: Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2:249-255. PMID: 16462705.
- Sengsuk C, Tangvarasittichai O, Chantanaskulwong P, Pimanprom A, Wantaneeyawong S, Choowet A, Tangvarasittichai S: Association of iron overload with oxidative stress, hepatic damage and dyslipidemia in transfusion-dependent β-thalassemia/HbE patients. Indian Journal of Clinical Biochemistry. 2014; 29:298-305. https://doi.org/10.1007/s12291-013-0376-2.
- Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J: Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-96. https://doi.org/10.1182/blood-2002-06-1704.
- Suman R, Sanadhya A, Meena P, Singh J, Jain R, Meena S. Lipid profile in children of β-thalassemia mayor and their correlation with serum ferritin. Int J Contemp Pediatr. 2017;4: 543-547. DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20170706.
- Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama; 285: 2486-2497. doi:10.1001/jama.285.19.2486 https://doi.org/10.1001/jama.285.19.2486.
- Kaltwassen JP, Gottschalk. Erythropoietin and iron. Kidney International Supplements. 1999; 69:49-56. https://doi.org/10.1046/j.1523-1755.1999.055Suppl.69049.x.
- Mansi KM, Aburjaf TA. Lipid profile in Jordian children with β thalassemia major. UHOD. 2008;18:93-8. http://www.uhod.org/pdf/PDF_317.pdf.
- Low LC. Growth of children with β-thalassemia major. The Indian Journal of Pediatrics. 2005;72:159-164. https://doi.org/10.1007/BF02760702.
- Patne AB, Hisalkar PJ, Gaikwad SB. Lipid abnormalities in patients of beta thalassaemia major. Int. J. Pharm. Sci. 2012;2: 106-112. http://www.ijpbs.com/ijpbsadmin/upload/ijpbs_50cdc93cc53f6.pdf.
- Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. BioMed research international, 2015. https://doi.org/10.1155/2015/813098.
- Suman RL, Sanadhya A, Meena P, Singh J, Jain R, Meena S. Lipid profile in children of β-thalassemia major and their correlation with serum ferritin. Int J Contemp Pediatr. 2017; 4:543-7.
DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20170706.
- Kready, H. O., Mohammed, M., Salem, M., & Al-Karwi, A. S. (2023). SCREENING AND DIAGNOSIS OF BETA-THALASSEMIA DEPENDING ON HBA2 AND BLOOD FILM IN BAGHDAD CITY. World, 2(6).